LLS TAP: Expanding the Possible with Next-Generation Cell Therapies

"Funding from leaders like LLS TAP helps fuel the progress of our clinical development program, bringing next-generation treatments that much closer to patients. We're particularly excited to be working with LLS TAP because it gives us access to their deep knowledge of blood cancer and their network of patients and drug development experts."  

Rachel Haurwitz, Ph.D., Co-Founder, President and Chief Executive Officer of Caribou Biosciences

Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) for a live one-hour discussion panel.


  • LLS commitment to cell therapy
  • Moderated discussion with TAP portfolio partners from:
    • Abintus Bio
    • Caribou Biosciences
    • Carisma Therapeutics
    • NexImmune
  • Q&A


Friday, Jan. 21, 2022

12 noon EST/9 am PST
via Zoom


Register to learn more. 

Follow LLS